ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017

Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.

Viralkumar Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.